08:48:57 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-06-07 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning IRRAS 0.00 SEK
2022-05-24 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-16 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-07-15 Extra Bolagsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2021-04-28 Årsstämma 2021
2021-02-16 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2020-04-28 Årsstämma 2020
2020-03-02 Extra Bolagsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-15 Ordinarie utdelning IRRAS 0.00 SEK
2019-05-15 Kvartalsrapport 2019-Q1
2019-05-14 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-06-04 Ordinarie utdelning IRRAS 0.00 SEK
2018-05-29 Kvartalsrapport 2018-Q1

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
IRRAS är verksamma inom medicinteknik. Bolaget är inriktade mot att utveckla lösningar för kirurgiska ingrepp vid hjärnsjukdomar. Bolaget har för närvarande utvecklat en teknologisk plattform som fokuserar på hantering av en rad delmoment vid hemorragisk stroke och kronisk subduralhematom, främst vid vätskehantering och intrakraniella blödningar. Bolaget har sitt huvudkontor i Stockholm.
2022-10-05 08:30:00
  • IRRAS will exhibit at the upcoming Congress of Neurological Surgeons (CNS) annual meeting in San Francisco, CA, from October 8 - 12, 2022, and the Neurocritical Care Society (NCS) annual meeting in San Antonio, TX, on October 17 - 21, 2022.
  • IRRAS will participate in the "Neurotrauma Across the Lifespan and Around the World" symposium at CNS on Sunday, October 9, 2022, beginning at 0800 PDT, which will provide hands-on product training to symposium attendees.
  • During CNS, Dr. Behnam Rezai Jahromi, a neurosurgeon from Helsinki University Hospital, will present a scientific poster titled "Active Cerebrospinal Fluid (CSF) Exchange and Removal of Subarachnoid Hemorrhage (SAH) to Reduce Shunt Dependency."

Stockholm, October 5, 2022 - IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced its plans to participate in the upcoming annual meetings of the Congress of Neurological Surgeons in San Francisco, CA, from October 8 - 12, 2022, and the Neurocritical Care Society in San Antonio, TX, from October 17 - 21, 2022.

Both meetings are well-respected and highly engaging conferences that bring together neurosurgeons, neurointensivists, and other healthcare professionals from around the world to enhance health and improve lives through the advancement of neurosurgical education and scientific exchange. 

During CNS, IRRAS will exhibit at booth #332, and, at NCS, IRRAS' team will be available at booth #513 to meet with attendees and provide demonstrations of the IRRAflow and Hummingbird neuromonitoring product lines.  Attendees at both conferences are encouraged to visit the IRRAS booths to learn more.

Also at CNS, IRRAS will participate in an all-day symposium where international experts will present their unique perspectives on neurotrauma management to integrate best practices and emerging evidence to optimize outcomes. The symposium will include a product demonstration station, where IRRAflow, the world's first active fluid exchange system, and the Hummingbird ICP advanced neuromonitoring product line will be showcased. Details are provided below.

Symposium Details

Title: "SYM11: Neurotrauma Across the Lifespan and Around the World"
Date: Sunday, October 9, 2022
Time: 0800 to 1615 PDT
Location: Moscone Center, Room 2009

In addition to the neurotrauma symposium participation at CNS, clinical data regarding the use of the IRRAflow system will also be presented. Dr. Behnam Rezai Jahromi, a neurosurgeon from Helsinki University Hospital, will present the poster, titled "Active CSF Exchange and Removal of SAH to Reduce Shunt Dependency," which will be available for review, both in-person and online.

"October will be an exciting month for IRRAS, and we are excited for the opportunity to partner with the Congress of Neurological Surgeons and the Neurocritical Care Society to participate in their upcoming annual meetings," said Will Martin, President and Chief Executive Officer of IRRAS. "Our team is looking forward to meeting with attendees in person at both of these important meetings to build brand awareness for our IRRAflow and Hummingbird product lines and highlight the growing commercial adoption and clinical evidence base." 

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on October 5, 2022, at 8:30 (CET).